Other formats:
BibTeX
LaTeX
RIS
@article{2219059,
author = {Duraisamy, Ganesh S. and Jo, Eunji and Huvarová, Ivana and Park, KyuandHo P. and Heger, Zbyněk and Adam, Vojtěch and Růžek, Daniel and Windisch, Marc P. and Miller, Andrew D.},
article_number = {9},
doi = {http://dx.doi.org/10.1016/j.heliyon.2022.e10465},
keywords = {Ginsenoside; Hepatitis B virus; Lamivudine; Nucleoside/nucleotide analogues; Hepatitis B surface protein; Hepatitis B surface antigen; Chronic hepatitis B virus; Drug combinations},
language = {eng},
issn = {2405-8440},
journal = {Heliyon},
title = {Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion.},
url = {https://doi.org/10.1016/j.heliyon.2022.e10465},
volume = {8},
year = {2022}
}
TY - JOUR
ID - 2219059
AU - Duraisamy, Ganesh S. - Jo, Eunji - Huvarová, Ivana - Park, Kyu-Ho P. - Heger, Zbyněk - Adam, Vojtěch - Růžek, Daniel - Windisch, Marc P. - Miller, Andrew D.
PY - 2022
TI - Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion.
JF - Heliyon
VL - 8
IS - 9
SP - 1-13
EP - 1-13
PB - Elsevier
SN - 24058440
KW - Ginsenoside
KW - Hepatitis B virus
KW - Lamivudine
KW - Nucleoside/nucleotide analogues
KW - Hepatitis B surface protein
KW - Hepatitis B surface antigen
KW - Chronic hepatitis B virus
KW - Drug combinations
UR - https://doi.org/10.1016/j.heliyon.2022.e10465
N2 - Ginsenosides are a class of natural steroid glycosides and triterpene saponins found in Panax ginseng. After screening of a commercial ginsenoside compound library for low cellular cytotoxicity and the ability to mediate efficient reductions in hepatitis B virus (HBV) mRNA expression levels in HepG2.2.15 cells, three ginsenosides (Rg6, Rh4, and Rb3) are selected. Thereafter, using the same cellular model, all three ginsenosides are shown to mediate efficient, selective inhibition of HBV mRNA expression levels, and also interfere with the secretion of both HBV particles and hepatitis B surface antigen (HBsAg). Drug combination studies are performed in both HepG2.2.15 and HBV-infected HepG2-NTCPsec+ cell models with the selected ginsenosides and lamivudine (LMV), a nucleoside analogue used to treat chronic hepatitis B (CHB) infections. These studies, involving RT-qPCR and ELISA, suggest that Rh4/LMV combinations in particular act synergistically to inhibit the secretion of HBV particles and HBsAg. Therefore, on the assumption that appropriate in vivo data are in future agreement, Rh4, in particular, might be used in combination with nucleoside/nucleotide analogues (NUCs) to devise an effective, cost-efficient combination therapy for the treatment of patients with CHB infections.
ER -
DURAISAMY, Ganesh S., Eunji JO, Ivana HUVAROVÁ, Kyu-Ho P. PARK, Zbyněk HEGER, Vojtěch ADAM, Daniel RŮŽEK, Marc P. WINDISCH and Andrew D. MILLER. Selected ginsenosides interfere efficiently with hepatitis B virus mRNA expression levels and suppress viral surface antigen secretion. \textit{Heliyon}. Elsevier, 2022, vol.~8, No~9, p.~1-13. ISSN~2405-8440. Available from: https://dx.doi.org/10.1016/j.heliyon.2022.e10465.
|
